Gilead twice-yearly HIV shot delivers zero infections in trial
21 Jun 2024
Phase 3Clinical ResultClinical Study
Gilead Sciences' experimental HIV drug, lenacapavir, has shown wildly promising results in preventing infection among women in the first phase 3 HIV prevention trial ever to show zero infections.
The twice-yearly injection was compared to daily oral Truvada, a current standard for HIV prevention.
In the PURPOSE 1 trial, none of the over 2,100 women given lenacapavir contracted HIV, whereas 16 infections occurred in the Truvada group. These results were significant enough for the trial's independent monitoring board to recommend stopping the blinded phase and offering lenacapavir to all participants.
Gilead is conducting another large trial, PURPOSE 2, expected to deliver results in late 2024 or early 2025. This trial will assess the effectiveness of twice-yearly lenacapavir for PrEP in a broader group, including cisgender men who have sex with men, transgender individuals, and gender-nonbinary people across several countries.
Lenacapavir is designed to be a long-acting alternative to daily medications for HIV prevention. If approved, it could help address challenges with adherence to daily pills. The goal now is to submit a regulatory filing for lenacapavir for PrEP with results from both PURPOSE 1 and PURPOSE 2.
In the U.S., the HIV National Strategic Plan uses viral suppression as the main indicator of success. Specifically, the U.S. goal is for 86% of people living with HIV to be virally suppressed on antiretroviral treatment by 2030.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.